SavedAdd your journal

Journals / Türkiye Çocuk Hastalıkları Dergisi / 2014 / Cilt: 8 - Sayı: 4

Suicide Behaviour After Montelukast Usage: A Case Report

Montelukast Kullanımı Sonrası İnti̇har Düşüncesi̇ ve Davranışı Gösteren Olgu

Fatih ÇELMELİ
Gamze ÇELMELİ
Aslı Sürer ADANIR
Doğa TÜRKKAHRAMAN
Pages
1–1
Publication Date
2014-04-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The complete resolution of the symptoms was seen upon the withdrawal of the medication

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Montelukast, a leukotriene receptor antagonistis a commonly prescribed medication in management of asthma in children.
📊
Key Findings & Data:It has been associated with increased risk of various neuropsychiatric events.
💡
Conclusion & Impact:The complete resolution of the symptoms was seen upon the withdrawal of the medication
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Çocuk · İntihar · Lökotrien reseptör antagonistleri

Abstract

Montelukast, a leukotriene receptor antagonistis a commonly prescribed medication in management of asthma in children. It has been associated with increased risk of various neuropsychiatric events. Here, we report a young boy who presents a number of unusual neuropsychiatric events (suicide behavior) after montelukast usage. The complete resolution of the symptoms was seen upon the withdrawal of the medication

Özet

Bir lökotrien reseptör antagonisti olan montelukast çocukluk çağı astım tedavisinde sıklıkla kullanılan bir ajandır. İlacın çeşitli nöropsikiyatrik yan etkileri giderek artan bir şekilde rapor edilmektedir. Bu olgu sunumunda, daha öncesinde genetik yatkınlığı ve psikolojik sorunu olmayan, montelukast kullanımı sonrası depresyon ve intihar düşüncesi/davranışı sergileyen, ilaç kesilmesi ile yakınmaları tamamen kaybolan bir olguyu rapor ediyoruz.

🔖

Cite This Article

ÇELMELİ, F., ÇELMELİ, G., ADANIR, A. S., TÜRKKAHRAMAN, D. (2014). Suicide Behaviour After Montelukast Usage: A Case Report. Türkiye Çocuk Hastalıkları Dergisi, Cilt: 8 - Sayı: 4, 1–1. https://ajindex.com/articles/707603

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31: 143-78.
  2. Full Drug Prescribing information, MERCK & CO., INC. available at www.singulair.com/montelukast_sodium/hcp/asthma/prescribing- information.jsp accessed 17/09/10. Philip G, Hustad CM, Malice MP, Noonan G, Ezekowitz A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:699-706.
  3. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. Engl J Med 1998;339:147-52. Türkiye Çocuk Hast Derg/Turkish J Pediatr Dis / 2014; 4: 212-214
  4. Wallerstedt SM, Brunlof G, Sundstrom A, Eriksson AL. Montelukast and psychiatric disorders in children. Pharmacoepidemiol Drug Saf 2009;18:858-64.
  5. Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009;124:691-6.
  6. Skillman KL, Stumpf JL. Montelukast-induced anxiety in two pediatric patients. Pharmacotherapy 2011;31:524 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.